Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 17, 1998

View Archived Issues

Sugen: Q2 1998 highlights

Aquila Biopharmaceuticals: Q2 1998 highlights

Combination therapy with naltrexone, TA-0910 and fluoxetine is an effective treatment for alcoholism

Phase II trial of MGI Pharma's anticancer drug has commenced

New antitumor agents isolated by Sagami

Novel antiandrogens in early development at Yamanouchi

New cerebroprotective agents described by Japanese team

Otsuka describes antihyperglycemic effects of coumarin derivatives

New anti-H. pylori agents in development at Mitsubishi Chemical

Isolation and antibiotic activity of spiroximicin reported

Zeneca claims factor Xa inhibitors with antithrombotic/anticoagulant activity

Novel antithrombotic agents added to the pipeline at NicOx

Results announced from primate studies of Nabi-Civacir

Gidazepam, a new benzodiazepine anxiolytic with potential in asthenic disorders

Unique agent for cognition disorders: GTS-21, a nicotinic acetylcholine agonist

No negative cardiovascular effects seen in dogs administered NC-100100

FDA okays use of Engerix-B in patients with chronic HCV infection

Synagis submitted for review by EMEA; product now available in U.S.

PST-2107, an inotropic agent with potential to outshine digoxin

Novel venotropic agent discovered by Innothera

Positive inotropic agent YS-49 shows potential in the treatment of septic shock

Eisai files for Japanese approval of AD treatment agent

EC approval granted for Lilly's SERM, Evista

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 22, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.